Journal
CURRENT DRUG TARGETS
Volume 11, Issue 5, Pages 576-585Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138945010791011965
Keywords
Aggrecanase; interleukin-1; matrix metalloproteinase; macrophage; osteoarthritis; synovium; tumour necrosis factor alpha
Categories
Funding
- Arthritis Research Campaign (UK) [W0596, 13172, 14570, 18893]
Ask authors/readers for more resources
The great success of targeted biologic therapy against rheumatoid arthritis (RA) in recent years has meant that much research has been devoted to investigating the pathophysiology of osteoarthritis (OA) in the hope of defining novel therapeutic targets. In contrast to RA, with its pannus and erosions, OA has long been thought of as a degenerative disease of cartilage, with secondary bony damage and osteophytes. But in recent years, the importance of the synovium, and in particular the synovial macrophages, in OA, has been highlighted in both in vitro and in vivo studies. This review will discuss the potential of synovial macrophages and their mediators, in particular the proinflammatory cytokines tumour necrosis factor and interleukin-1, as potential therapeutic targets in OA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available